Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors
Posted on September 06, 2011 at 09:18 AM EDT
Novartis announced today that the European Commission has approved Afinitor® (everolimus) tablets for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive disease[3].